Perspective Therapeutics Doses First Meningioma Patient with [212Pb]VMT-alpha-NET

Perspective Therapeutics announced that the first meningioma patient was dosed with [212Pb]VMT-alpha-NET in the Company's ongoing Phase 1/2a study. The new cohort is intended to evaluate the safety, dosimetry, and preliminary anti-tumor activity of lead-based alpha-particle therapy with [212Pb]VMT-alpha-NET for meningioma. The initiation of the meningioma cohort reflects The Company's broader strategy to evaluate [212Pb]VMT-alpha-NET across somatostatin receptor subtype 2 - expressing tumor types beyond neuroendocrine tumors, or NETs. Meningiomas are the most common primary brain tumors in adults, accounting for ~40% of all central nervous system tumors diagnosed annually in the U.S. Approximately 20% of all diagnosed meningioma cases are grades 2 and 3 by World Health Organization 2021 grading, while approximately 30% of patients with diagnosed grade 1 disease either have inoperable disease or experience recurrence of their disease. Although surgery and radiation remain standard treatments, patients with recurrent, progressive, or unresectable disease often face limited therapeutic options and poor long-term outcomes.2 Meningiomas consistently express SSTR24, making them an attractive target for targeted radiopharmaceutical therapy. Perspective designed [212Pb]VMT-alpha-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study of [212Pb]VMT-alpha-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies.